We are delighted to announce that Prof. Karim Fizazi, a distinguished medical oncologist at Institut Gustave Roussy (France), has joined our Medical Advisory Board.
Internationally renowned for his expertise in prostate cancer and oncology, Prof. Fizazi brings over two decades of experience in immunotherapy and clinical trials. He established the Prostate Cancer Consortium in Europe (PEACE) and leads the first two large European Phase III trials: PEACE-1 and PEACE-2.
He is also Associate Editor of the European Journal of Cancer and has contributed significantly to the scientific community with more than 450 publications in high-impact journals.
His insights will guide our strategy in advancing our lead program, MQI-201, into the clinics.
« We will be highly interested in having MQI-201, a first-in-class anti-TRPV6 novel antibody with a proven preclinical efficacy & safety, in therapeutic clinical trials in the prostate cancer indication which is still characterized by a high medical need », said Prof. K. Fizazi.
